Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [125I]anti-C3d mAb.

Foss CA, Kulik L, Ordonez AA, Jain SK, Michael Holers V, Thurman JM, Pomper MG.

Mol Imaging Biol. 2018 Jul 11. doi: 10.1007/s11307-018-1228-5. [Epub ahead of print]

PMID:
29998399
2.

Imaging Pulmonary Foreign Body Reaction Using [125I]iodo-DPA-713 SPECT/CT in Mice.

Sanchez-Bautista J, Foss CA, Ordonez AA, Klunk MH, Jain SK.

Mol Imaging Biol. 2018 Jul 9. doi: 10.1007/s11307-018-1249-0. [Epub ahead of print]

PMID:
29987615
3.

Biodistribution and Radiation Dosimetry of 124I-iodo-DPA-713, a PET Radiotracer for Macrophage-Associated Inflammation.

Foss CA, Plyku D, Ordonez AA, Sanchez-Bautista J, Rosenthal HB, Minn IL, Lodge MA, Pomper MG, Sgouros G, Jain SK.

J Nucl Med. 2018 Apr 26. pii: jnumed.117.207431. doi: 10.2967/jnumed.117.207431. [Epub ahead of print]

PMID:
29700124
4.

Imaging Macrophage-associated Inflammation.

Foss CA, Sanchez-Bautista J, Jain SK.

Semin Nucl Med. 2018 May;48(3):242-245. doi: 10.1053/j.semnuclmed.2017.12.002. Epub 2018 Feb 13. Review.

PMID:
29626941
5.

[125 I]IodoDPA-713 Binding to 18 kDa Translocator Protein (TSPO) in a Mouse Model of Intracerebral Hemorrhage: Implications for Neuroimaging.

Bonsack F, Foss CA, Arbab AS, Alleyne CH Jr, Pomper MG, Sukumari-Ramesh S.

Front Neurosci. 2018 Feb 22;12:66. doi: 10.3389/fnins.2018.00066. eCollection 2018.

6.

Desmin Phosphorylation Triggers Preamyloid Oligomers Formation and Myocyte Dysfunction in Acquired Heart Failure.

Rainer PP, Dong P, Sorge M, Fert-Bober J, Holewinski RJ, Wang Y, Foss CA, An SS, Baracca A, Solaini G, Glabe CG, Pomper MG, Van Eyk JE, Tomaselli GF, Paolocci N, Agnetti G.

Circ Res. 2018 May 11;122(10):e75-e83. doi: 10.1161/CIRCRESAHA.117.312082. Epub 2018 Feb 26.

PMID:
29483093
7.

Translocator protein (TSPO) and stress cascades in mouse models of psychosis with inflammatory disturbances.

Fukudome D, Hayes LN, Faust TE, Foss CA, Kondo MA, Lee BJ, Saito A, Kano SI, Coughlin JM, Kamiya A, Pomper MG, Sawa A, Niwa M.

Schizophr Res. 2018 Feb 2. pii: S0920-9964(18)30035-5. doi: 10.1016/j.schres.2018.01.015. [Epub ahead of print]

PMID:
29398205
8.

Correction: Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.

Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, Weirich G, Panchal P, Gopalan A, Zurita J, Achilefu S, Chiosis G, Ponomarev V, Schwaiger M, Carver BS, Pomper MG, Grimm J.

J Exp Med. 2018 Jan 2;215(1):377. doi: 10.1084/jem.2017105211212017c. Epub 2017 Nov 28. No abstract available.

9.

Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.

Kaittanis C, Andreou C, Hieronymus H, Mao N, Foss CA, Eiber M, Weirich G, Panchal P, Gopalan A, Zurita J, Achilefu S, Chiosis G, Ponomarev V, Schwaiger M, Carver BS, Pomper MG, Grimm J.

J Exp Med. 2018 Jan 2;215(1):159-175. doi: 10.1084/jem.20171052. Epub 2017 Nov 15. Erratum in: J Exp Med. 2017 Nov 28;:.

10.

PEGylated TRAIL ameliorates experimental inflammatory arthritis by regulation of Th17 cells and regulatory T cells.

Park JS, Oh Y, Park O, Foss CA, Lim SM, Jo DG, Na DH, Pomper MG, Lee KC, Lee S.

J Control Release. 2017 Dec 10;267:163-171. doi: 10.1016/j.jconrel.2017.10.004. Epub 2017 Oct 7.

PMID:
29017854
11.

Imaging Macrophage Accumulation in a Murine Model of Chronic Pancreatitis with 125I-Iodo-DPA-713 SPECT/CT.

Foss CA, Liu L, Mease RC, Wang H, Pasricha P, Pomper MG.

J Nucl Med. 2017 Oct;58(10):1685-1690. doi: 10.2967/jnumed.117.189571. Epub 2017 May 18.

12.

High Serum Stability of Collagen Hybridizing Peptides and Their Fluorophore Conjugates.

Bennink LL, Smith DJ, Foss CA, Pomper MG, Li Y, Yu SM.

Mol Pharm. 2017 Jun 5;14(6):1906-1915. doi: 10.1021/acs.molpharmaceut.7b00009. Epub 2017 May 8.

PMID:
28445649
13.

Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools.

Nováková Z, Foss CA, Copeland BT, Morath V, Baranová P, Havlínová B, Skerra A, Pomper MG, Barinka C.

Prostate. 2017 May;77(7):749-764. doi: 10.1002/pros.23311. Epub 2017 Mar 1.

PMID:
28247415
14.

Development of Radiolabeled Ligands Targeting the Glutamate Binding Site of the N-Methyl-d-aspartate Receptor as Potential Imaging Agents for Brain.

Tamborini L, Chen Y, Foss CA, Pinto A, Horti AG, Traynelis SF, De Micheli C, Mease RC, Hansen KB, Conti P, Pomper MG.

J Med Chem. 2016 Dec 22;59(24):11110-11119. Epub 2016 Dec 6.

15.

111In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues.

Banerjee SR, Foss CA, Horhota A, Pullambhatla M, McDonnell K, Zale S, Pomper MG.

Biomacromolecules. 2017 Jan 9;18(1):201-209. doi: 10.1021/acs.biomac.6b01485. Epub 2016 Dec 21.

16.

MR-Guided Delivery of Hydrophilic Molecular Imaging Agents Across the Blood-Brain Barrier Through Focused Ultrasound.

Airan RD, Foss CA, Ellens NP, Wang Y, Mease RC, Farahani K, Pomper MG.

Mol Imaging Biol. 2017 Feb;19(1):24-30. doi: 10.1007/s11307-016-0985-2.

17.

[(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Yang X, Mease RC, Pullambhatla M, Lisok A, Chen Y, Foss CA, Wang Y, Shallal H, Edelman H, Hoye AT, Attardo G, Nimmagadda S, Pomper MG.

J Med Chem. 2016 Jan 14;59(1):206-18. doi: 10.1021/acs.jmedchem.5b01268. Epub 2015 Dec 16.

18.

Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.

Castanares MA, Copeland BT, Chowdhury WH, Liu MM, Rodriguez R, Pomper MG, Lupold SE, Foss CA.

Prostate. 2016 Feb;76(2):215-25. doi: 10.1002/pros.23115. Epub 2015 Oct 26.

19.

Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Kiess AP, Banerjee SR, Mease RC, Rowe SP, Rao A, Foss CA, Chen Y, Yang X, Cho SY, Nimmagadda S, Pomper MG.

Q J Nucl Med Mol Imaging. 2015 Sep;59(3):241-68. Epub 2015 Jul 24. Review.

20.

Auger Radiopharmaceutical Therapy Targeting Prostate-Specific Membrane Antigen.

Kiess AP, Minn I, Chen Y, Hobbs R, Sgouros G, Mease RC, Pullambhatla M, Shen CJ, Foss CA, Pomper MG.

J Nucl Med. 2015 Sep;56(9):1401-1407. doi: 10.2967/jnumed.115.155929. Epub 2015 Jul 16.

21.

Improved intervention of atherosclerosis and cardiac hypertrophy through biodegradable polymer-encapsulated delivery of glycosphingolipid inhibitor.

Mishra S, Bedja D, Amuzie C, Foss CA, Pomper MG, Bhattacharya R, Yarema KJ, Chatterjee S.

Biomaterials. 2015 Sep;64:125-135. doi: 10.1016/j.biomaterials.2015.06.001. Epub 2015 Jun 3.

22.

Molecular imaging of inflammation in the ApoE -/- mouse model of atherosclerosis with IodoDPA.

Foss CA, Bedja D, Mease RC, Wang H, Kass DA, Chatterjee S, Pomper MG.

Biochem Biophys Res Commun. 2015 May 22;461(1):70-5. doi: 10.1016/j.bbrc.2015.03.171. Epub 2015 Apr 6.

23.

Preclinical evaluation of 86Y-labeled inhibitors of prostate-specific membrane antigen for dosimetry estimates.

Banerjee SR, Foss CA, Pullambhatla M, Wang Y, Srinivasan S, Hobbs RF, Baidoo KE, Brechbiel MW, Nimmagadda S, Mease RC, Sgouros G, Pomper MG.

J Nucl Med. 2015 Apr;56(4):628-34. doi: 10.2967/jnumed.114.149062. Epub 2015 Feb 26.

24.

Evaluation of a PSMA-targeted BNF nanoparticle construct.

Behnam Azad B, Banerjee SR, Pullambhatla M, Lacerda S, Foss CA, Wang Y, Ivkov R, Pomper MG.

Nanoscale. 2015 Mar 14;7(10):4432-42. doi: 10.1039/c4nr06069e.

25.

Isolated spinal cord contusion in rats induces chronic brain neuroinflammation, neurodegeneration, and cognitive impairment. Involvement of cell cycle activation.

Wu J, Stoica BA, Luo T, Sabirzhanov B, Zhao Z, Guanciale K, Nayar SK, Foss CA, Pomper MG, Faden AI.

Cell Cycle. 2014;13(15):2446-58. doi: 10.4161/cc.29420.

26.

Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice.

Ordonez AA, Pokkali S, DeMarco VP, Klunk M, Mease RC, Foss CA, Pomper MG, Jain SK.

Antimicrob Agents Chemother. 2015 Jan;59(1):642-9. doi: 10.1128/AAC.04180-14. Epub 2014 Nov 17.

27.

⁶⁴Cu-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer.

Banerjee SR, Pullambhatla M, Foss CA, Nimmagadda S, Ferdani R, Anderson CJ, Mease RC, Pomper MG.

J Med Chem. 2014 Mar 27;57(6):2657-69. doi: 10.1021/jm401921j. Epub 2014 Mar 7.

28.
29.

Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713.

Foss CA, Harper JS, Wang H, Pomper MG, Jain SK.

J Infect Dis. 2013 Dec 15;208(12):2067-74. doi: 10.1093/infdis/jit331. Epub 2013 Jul 30.

30.

Effect of chelators on the pharmacokinetics of (99m)Tc-labeled imaging agents for the prostate-specific membrane antigen (PSMA).

Ray Banerjee S, Pullambhatla M, Foss CA, Falk A, Byun Y, Nimmagadda S, Mease RC, Pomper MG.

J Med Chem. 2013 Aug 8;56(15):6108-21. doi: 10.1021/jm400823w. Epub 2013 Jul 22.

31.

Radiochemical synthesis and in vivo evaluation of [18F]AZ11637326: an agonist probe for the α7 nicotinic acetylcholine receptor.

Ravert HT, Dorff P, Foss CA, Mease RC, Fan H, Holmquist CR, Phillips E, McCarthy DJ, Heys JR, Holt DP, Wang Y, Endres CJ, Dannals RF, Pomper MG.

Nucl Med Biol. 2013 Aug;40(6):731-9. doi: 10.1016/j.nucmedbio.2013.04.005. Epub 2013 May 13.

PMID:
23680470
32.

PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Mease RC, Foss CA, Pomper MG.

Curr Top Med Chem. 2013;13(8):951-62. Review.

33.

Molecular imaging of conscious, unrestrained mice with AwakeSPECT.

Baba JS, Endres CJ, Foss CA, Nimmagadda S, Jung H, Goddard JS, Lee S, McKisson J, Smith MF, Stolin AV, Weisenberger AG, Pomper MG.

J Nucl Med. 2013 Jun;54(6):969-76. doi: 10.2967/jnumed.112.109090. Epub 2013 Mar 27.

34.

Subcortical dopaminergic deficits in a DISC1 mutant model: a study in direct reference to human molecular brain imaging.

Jaaro-Peled H, Niwa M, Foss CA, Murai R, de Los Reyes S, Kamiya A, Mateo Y, O'Donnell P, Cascella NG, Nabeshima T, Guilarte TR, Pomper MG, Sawa A.

Hum Mol Genet. 2013 Apr 15;22(8):1574-80. doi: 10.1093/hmg/ddt007. Epub 2013 Jan 11.

35.

Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation.

Sagar D, Lamontagne A, Foss CA, Khan ZK, Pomper MG, Jain P.

J Neuroinflammation. 2012 Oct 26;9:245. doi: 10.1186/1742-2094-9-245.

36.

Targeting collagen strands by photo-triggered triple-helix hybridization.

Li Y, Foss CA, Summerfield DD, Doyle JJ, Torok CM, Dietz HC, Pomper MG, Yu SM.

Proc Natl Acad Sci U S A. 2012 Sep 11;109(37):14767-72. doi: 10.1073/pnas.1209721109. Epub 2012 Aug 27.

37.

GCPII imaging and cancer.

Foss CA, Mease RC, Cho SY, Kim HJ, Pomper MG.

Curr Med Chem. 2012;19(9):1346-59. Review.

38.

2-(3-{1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer.

Chen Y, Pullambhatla M, Foss CA, Byun Y, Nimmagadda S, Senthamizhchelvan S, Sgouros G, Mease RC, Pomper MG.

Clin Cancer Res. 2011 Dec 15;17(24):7645-53. doi: 10.1158/1078-0432.CCR-11-1357. Epub 2011 Oct 31.

39.

Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen.

Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG.

Angew Chem Int Ed Engl. 2011 Sep 19;50(39):9167-70. doi: 10.1002/anie.201102872. Epub 2011 Aug 22. No abstract available.

40.

Effects of recombinant human thyroid-stimulating hormone superagonists on thyroidal uptake of 18F-fluorodeoxyglucose and radioiodide.

Reinfelder J, Maschauer S, Foss CA, Nimmagadda S, Fremont V, Wolf V, Weintraub BD, Pomper MG, Szkudlinski MW, Kuwert T, Prante O.

Thyroid. 2011 Jul;21(7):783-92. doi: 10.1089/thy.2010.0394. Epub 2011 May 13.

PMID:
21568725
41.

A robust approach to enhance tumor-selective accumulation of nanoparticles.

Qiao Y, Huang X, Nimmagadda S, Bai R, Staedtke V, Foss CA, Cheong I, Holdhoff M, Kato Y, Pomper MG, Riggins GJ, Kinzler KW, Diaz LA Jr, Vogelstein B, Zhou S.

Oncotarget. 2011 Jan-Feb;2(1-2):59-68.

42.

Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Hillier SM, Maresca KP, Femia FJ, Marquis JC, Foss CA, Nguyen N, Zimmerman CN, Barrett JA, Eckelman WC, Pomper MG, Joyal JL, Babich JW.

Cancer Res. 2009 Sep 1;69(17):6932-40. doi: 10.1158/0008-5472.CAN-09-1682. Epub 2009 Aug 25.

43.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.

Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188. Epub 2009 Jul 7.

44.

Novel antisense oligonucleotides containing hydroxamate linkages: targeted iron-triggered chemical nucleases.

Miller MJ, Li H, Foss CA.

Biometals. 2009 Jun;22(3):491-510. doi: 10.1007/s10534-009-9206-7. Epub 2009 Jan 28.

45.

Serial imaging of human embryonic stem-cell engraftment and teratoma formation in live mouse models.

Pomper MG, Hammond H, Yu X, Ye Z, Foss CA, Lin DD, Fox JJ, Cheng L.

Cell Res. 2009 Mar;19(3):370-9. doi: 10.1038/cr.2008.329.

46.

Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG.

J Med Chem. 2008 Dec 25;51(24):7933-43. doi: 10.1021/jm801055h.

47.

Imaging virus-associated cancer.

Fu DX, Foss CA, Nimmagadda S, Ambinder RF, Pomper MG.

Curr Pharm Des. 2008;14(28):3048-65. Review.

48.

Bortezomib-induced enzyme-targeted radiation therapy in herpesvirus-associated tumors.

Fu DX, Tanhehco Y, Chen J, Foss CA, Fox JJ, Chong JM, Hobbs RF, Fukayama M, Sgouros G, Kowalski J, Pomper MG, Ambinder RF.

Nat Med. 2008 Oct;14(10):1118-22. doi: 10.1038/nm.1864. Epub 2008 Sep 7.

49.

Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).

Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper MG.

J Med Chem. 2008 Aug 14;51(15):4504-17. doi: 10.1021/jm800111u. Epub 2008 Jul 19.

50.

Spatio-temporal modification of collagen scaffolds mediated by triple helical propensity.

Wang AY, Foss CA, Leong S, Mo X, Pomper MG, Yu SM.

Biomacromolecules. 2008 Jul;9(7):1755-63. doi: 10.1021/bm701378k. Epub 2008 Jun 12.

Supplemental Content

Support Center